首页> 美国卫生研究院文献>BMJ Global Health >Initial success from a public health approach to hepatitis C testing treatment and cure in seven countries: the road to elimination
【2h】

Initial success from a public health approach to hepatitis C testing treatment and cure in seven countries: the road to elimination

机译:从公共卫生方法到六个国家的丙型肝炎测试治疗和治愈的初步成功:消除道路

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

With political will, modest financial investment and effective technical assistance, public sector hepatitis C virus (HCV) programmes can be established in low- and middle-income countries as a first step towards elimination. Seven countries, with support from the Clinton Health Access Initiative (CHAI) and partners, have expanded access to HCV treatment by combining programme simplification with market shaping to reduce commodity prices. CHAI has supported a multipronged approach to HCV programme launch in Cambodia, India, Indonesia, Myanmar, Nigeria, Rwanda and Vietnam including pricing negotiations with suppliers, policy development, fast-track registrations of quality-assured generics, financing advocacy and strengthened service delivery. Governments are leading programme implementation, leveraging HIV programme infrastructure/financing and focusing on higher-HCV prevalence populations like people living with HIV, people who inject drugs and prisoners. This manuscript aims to describe programme structure and strategies, highlight current commodity costs and outline testing and treatment volumes across these countries. Across countries, commodity costs have fallen from >US$100 per diagnostic test and US$750–US$900 per 12-week pan-genotypic direct-acting antiviral regimen to as low as US$80 per-cure commodity package, including WHO-prequalified generic drugs (sofosbuvir + daclatasvir). As of December 2019, 5900+ healthcare workers were trained, 2 209 209 patients were screened, and 120 522 patients initiated treatment. The cure (SVR12) rate was >90%, including at lower-tier facilities. Programmes are successfully implementing simplified, decentralised public health approaches. Combined with political will and affordable pricing, these efforts can translate into commitments to achieve global targets. However, to achieve elimination, additional investment in scale-up is required.
机译:随着政治意愿,适度的金融投资和有效的技术援助,公共部门丙型肝炎病毒(HCV)方案可以在低收入和中等收入国家确定作为消除的第一步。七个国家,通过克林顿卫生访问倡议(柴)和合作伙伴的支持,通过将计划简化与市场塑造相结合以降低商品价格,扩大了对HCV处理的访问。柴已经支持柬埔寨,印度,印度尼西亚,缅甸,尼日利亚,卢旺达和越南推出的HCV计划发布的多强手方法,包括与供应商,政策开发,质量保证泛型的快速登记,融资宣传和加强服务交付的定价谈判。政府是领先的方案实施,利用艾滋病毒计划基础设施/融资,并专注于与艾滋病毒患有艾滋病毒的人,注入毒品和囚犯的人们更高的HCV患病率。该手稿旨在描述方案结构和策略,突出当前商品成本和概述这些国家的测试和治疗卷。各种各样的商品成本从>每12周泛基因型直接抗病毒品灭活抗病毒方案的每诊断测试(每12周泛基因型为750美元)下降,每次治疗商品包装为80美元,其中包括谁 - 预章仿制药(Sofosbuvir + Daclatasvir)。截至2019年12月,培训了5900多名医疗保健工人,筛选了209例209例患者,120例患者发起治疗。固化(SVR12)率> 90%,包括在较低的设施。计划成功实施简化,分散的公共卫生方法。结合政治意愿和经济实惠的定价,这些努力可以转化为实现全球目标的承诺。但是,为了实现消除,需要额外的扩大投资。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号